NICE approves rivaroxaban for DVT and recurrent VTE

The direct factor Xa inhibitor rivaroxaban has been recommended for NHS use in two new indications.

It is estimated that there will be over 46,000 cases of acute DVT in England and Wales during 2012 | SCIENCE PHOTO LIBRARY
It is estimated that there will be over 46,000 cases of acute DVT in England and Wales during 2012 | SCIENCE PHOTO LIBRARY

NICE has recommended rivaroxaban (Xarelto) as an option for treating deep vein thrombosis (DVT) and for preventing recurrent DVT and pulmonary embolism after a diagnosis of acute DVT in adults.

The anticoagulant can also be prescribed on the NHS to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation, and to prevent venous thromboembolism (VTE) following total hip or knee replacement. 

Further details

NICE guidance on rivaroxaban in DVT

Further information:

View Xarelto drug record

Want news like this straight to your inbox?
Sign up for our bulletins

Read these next

New oral anticoagulant edoxaban launches

New oral anticoagulant edoxaban launches

Prescribers now have an additional option for non-warfarin-based...

Xarelto: first novel anticoagulant licensed for ACS

Xarelto: first novel anticoagulant licensed for ACS

Bayer has launched a new 2.5mg strength of Xarelto...

Eliquis approved for DVT and PE

Eliquis approved for DVT and PE

Eliquis (apixaban) is now licensed for the treatment...

Pradaxa now indicated for DVT and PE

Pradaxa now indicated for DVT and PE

Pradaxa (dabigatran) is now licensed for the treatment...

Xarelto licensed to treat pulmonary embolism

Xarelto licensed to treat pulmonary embolism

Xarelto (rivaroxaban) can now be prescribed for the...

NICE recommends rivaroxaban for stroke prevention in AF

NICE recommends rivaroxaban for stroke prevention in AF

Rivaroxaban (Xarelto) has been approved by NICE for...

New blood thinning agent approved for GPs in Scotland

New blood thinning agent approved for GPs in Scotland

Rivaroxaban for DVT and for stroke prevention in AF...

Xarelto: two new indications for oral anticoagulant

Xarelto: two new indications for oral anticoagulant

The direct oral factor Xa inhibitor, rivaroxaban (Xarelto),...



Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more